June 11, 2025
Mr. Carson (for himself, Mr. Auchincloss, Ms. Barragán, Ms. Budzinski, Ms. Craig, Mr. Doggett, Mr. Fields, Ms. Garcia of Texas, Ms. Goodlander, Mr. Gottheimer, Mr. Jackson of Illinois, Mr. Levin, Mr. Lynch, Ms. McBride, Mrs. McIver, Mr. Moulton, Mr. Mrvan, Ms. Ocasio-Cortez, Mr. Neal, Ms. Norton, Ms. Ross, Ms. Salinas, Ms. Schrier, and Ms. Strickland) introduced the following bill; which was referred to the Committee on Appropriations
To amend the Full-Year Continuing Appropriations and Extensions Act, 2025 to restore amounts available for Defense Health Agency research, development, test, and evaluation, including Congressionally Directed Medical Research Programs.
Section 1. Short title
This Act may be cited as the Medical Research for Our Troops Act
.
Sec. 2. Restoration of amounts for Defense Health Agency research, development, test, and evaluation
(a) In general
Section 1407(1) of the Full-Year Continuing Appropriations and Extensions Act, 2025 (Public Law 119–4) is amended—
(1)
by striking $40,395,072,000
and inserting $41,576,684,000
; and
(2)
by striking the 23rd comma and all that follows through the period at the end and inserting a period.
(b) Effective date
The amendments made by subsection (a) shall take effect as if included in the enactment of the Full-Year Continuing Appropriations and Extensions Act, 2025 (Public Law 119–4).
(c) Congressionally Directed Medical Research Programs
The funds made available for Congressionally Directed Medical Research Programs pursuant to section 1407(1) of the Full-Year Continuing Appropriations and Extensions Act, 2025 (Public Law 119–4), as amended by subsection (a), shall be implemented in levels and in a manner consistent with the Consolidated Appropriations Act, 2024 (Public Law 118–47). The Secretary of Defense shall—
(1)
ensure that such funds are used to support all research programs, peer-reviewed initiatives, and projects identified in the explanatory statement accompanying the Consolidated Appropriations Act, 2024 (Public Law 118–47); and
(2)
obligate and expend such funds in a manner that preserves program continuity, including adherence to all specified funding allocations and research priorities identified on pages 311 through 314 of such explanatory statement.